Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study.
Mason M, Warde P, Sydes M, Cowan R, James N, Kirkbride P, Langley R, Latham J, Moynihan C, Anderson J, Millet J, Nutall J, Moffat L, Parulekar W, Parmar M; National Cancer Institute of Canada Clinical Trials Group PR3/; Medical Research Council PR07 Trial Management Group. Mason M, et al. Among authors: parulekar w. Clin Oncol (R Coll Radiol). 2005 Jun;17(4):217-8. doi: 10.1016/j.clon.2005.02.013. Clin Oncol (R Coll Radiol). 2005. PMID: 15997913 No abstract available.
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32).
Hershman DL, Chen BE, Sathe C, Parulekar WR, Lemieux J, Ligibel JA, Gelmon KA, Whelan TJ, Goodwin PJ. Hershman DL, et al. Among authors: parulekar wr. Breast Cancer Res Treat. 2023 Jul;200(1):93-102. doi: 10.1007/s10549-023-06922-2. Epub 2023 May 9. Breast Cancer Res Treat. 2023. PMID: 37157006 Clinical Trial.
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Moore MJ, et al. Among authors: parulekar w. J Clin Oncol. 2023 Oct 20;41(30):4714-4720. doi: 10.1200/JCO.22.02770. J Clin Oncol. 2023. PMID: 37847995
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, et al. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.
An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases.
Kerba M, Lourenco RA, Sahgal A, Cardet RF, Siva S, Ding K, Myrehaug SD, Masucci GL, Brundage M, Parulekar WR. Kerba M, et al. Among authors: parulekar wr. Int J Radiat Oncol Biol Phys. 2024 Jan 11:S0360-3016(24)00022-1. doi: 10.1016/j.ijrobp.2023.12.052. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38218455
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Carrier M, et al. N Engl J Med. 2019 Feb 21;380(8):711-719. doi: 10.1056/NEJMoa1814468. Epub 2018 Dec 4. N Engl J Med. 2019. PMID: 30511879 Clinical Trial.
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. Goodwin PJ, et al. Among authors: parulekar wr. J Clin Oncol. 2023 Dec 10;41(35):5356-5362. doi: 10.1200/JCO.23.00296. Epub 2023 Sep 11. J Clin Oncol. 2023. PMID: 37695982 Free PMC article. Clinical Trial.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Among authors: parulekar w. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
Parker C, Clarke N, Logue J, Payne H, Catton C, Kynaston H, Murphy C, Morgan R, Morash C, Parulekar W, Parmar M, Savage C, Stansfeld J, Sydes M; RADICALS Trial Management Group. Parker C, et al. Among authors: parulekar w. Clin Oncol (R Coll Radiol). 2007 Apr;19(3):167-71. doi: 10.1016/j.clon.2007.01.001. Epub 2007 Feb 7. Clin Oncol (R Coll Radiol). 2007. PMID: 17359901 Clinical Trial. No abstract available.
105 results